Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Abbott Laboratories's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $183.8B | |
|---|---|---|
| Revenue (ttm) | 48.2B | |
| Net income (ttm) | 4.7B | |
| EPS (ttm) | $2.69 | |
| Shares out | 1.7B | |
| P/E (trailing) | 38.2x | |
| P/E (forward) | 17.9x | |
| Dividend | $2.52 (2.45%) | |
| Volume | 4,052,721 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B | +0.7% |
| Gross profit | $23.21B | $22.32B | $20.04B | $21.33B | $24.61B | +1.5% |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | -1.1% |
| Net income | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B | -2.0% |
| EPS (diluted) | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | -1.4% |
| EBITDA | $12.16B | $11.89B | $10.61B | $10.83B | $11.55B | -1.3% |
| R&D | $2.74B | $2.89B | $2.74B | $2.84B | $2.94B | +1.8% |
| SG&A | $11.32B | $11.25B | $10.95B | $11.70B | $12.33B | +2.2% |
Recent company headlines from major financial publishers.
The base scenario assumes the FY2027 revenue and adjusted-EPS forecasts are achieved. It then assumes growth fades toward a mature-company pace; that post-FY2027 fade is a valuation premise, not a reported result.
Broader growth persistence would lift revenue, earnings, and cash beyond the period directly supported by dated forecasts.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.3% | $99.9 | $106 | $115 | $127 | $146 |
| 6.3% | $87.9 | $91.7 | $96.6 | $103 | $111 |
| 7.3% | $79.6 | $82.1 | $86.7 | $88.8 | $93.4 |
| 8.3% | $73.4 | $75.2 | $77.2 | $79.6 | $82.5 |
| 9.3% | $68.7 | $69.9 | $71.4 | $73.0 | $74.9 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
